Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is a biopharmaceutical company with a promising pipeline of next-generation programmed T-cell therapies that are tailored to address specific diseases and improve patient outcomes. The company's recent virtual investor event highlighted the strong clinical profile of their lead therapy, Aucatzyl, and the potential for market expansion into earlier lines of therapy in pediatric ALL. Intellectual property protection and financial concerns are important risks to consider, but impressive real-world data and the potential for frontline use are positive indicators for the company's future success.

Bears say

Autolus Therapeutics is a biopharmaceutical company that is developing promising next-generation programmed T-cell therapies for cancer treatment, but there are several underlying risks and uncertainties. These include potential data readouts that may not meet expectations, competitive pressures from other companies with similar technologies, and potential safety concerns and adverse events associated with CAR-T therapy administration. Additionally, while initial data for their lead candidate AUTO3 in pediatric B-ALL patients has shown positive results, there is no guarantee of long-term and sustained remissions. Due to these risks, the outlook on Autolus's stock is negative from a financial analyst's perspective.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.